Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P382 Application of enhanced recovery after surgery in single-port laparoscopic partial small intestine resection in the treatment of Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y. LI, Z. Zhou, D. Yao, L. Zheng, Y. Duan, B. Liu, Y. Huang

Department of Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School, Shanghai, China

P383 The level of intestinal inflammation and fibrosis in resection specimens after preoperative anti-tumour necrosis factor-α treatment in patients with Crohn’s disease: a comparative pilot study

ECCO'20 Vienna

Year: 2020
Authors:

J. Torle1, P. Dabir2, U. Korsgaard3, J.J. Christiansen3, N. Qvist4, A. El-Hussuna5

1Regional Hospital Randers, Surgery, Randers, Denmark, 2Regional Hospital Randers-Denmark, Pathology, Randers, Denmark, 3Regional Hospital Randers, Pathology, Randers, Denmark, 4IBD Care- Surgical Research Unit, Odense University Hospital- Southern University of Denmark, Odense, Denmark, 5Aalborg University Hospital, Surgery, Aalborg, Denmark

P384 Lower infliximab trough levels are associated with higher bowel wall thickness in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

C. Frias Gomes1, B. Morão1, C. Neto Nascimento1, C. Gouveia1, C. Palmela1, J. Strecht2, J. Torres1

1Surgery Department- Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal, 2Radiology Department, Hospital Beatriz Ângelo, Loures, Portugal

P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

B. Verstockt1, S. Verstockt2, D. Alsaoud2, J. Sabino1, M. Ferrante1, S. Vermeire1

1IBD Leuven, 1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2KU Leuven, CHROMETA - Translational Research in Gastrointestinal Disorders, Leuven, Belgium

P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study

ECCO'20 Vienna

Year: 2020
Authors:

M.J. Casanova1, M. Chaparro2, O. Nantes3, J.M. Benítez4, M. Rojas-Feria5, J. Castro-Poceiro6, J.M. Huguet7, A. Martín-Cardona8, M. Aicart9, J. Tosca10, M.D.M. Martín-Rodríguez11, C. González-Muñoza12, M. Mañosa13, E. Leo-Carnerero14, L. Lamuela15, I. Pérez-Martínez16, L. Bujanda17, J. Hinojosa18, R. Pajares19, F. Argüelles-Arias20, J.L. Pérez-Calle21, G.E. Rodríguez-González22, J. Guardiola23, M. Barreiro-de Acosta24, F. Bermejo25, J. Barrio26, B. Beltrán27, F. Gomollón28, R. Lorente29, A. Gutierrez30, M. Domínguez-Cajal31, C. Dueñas32, A. Ponferrada-Díaz33, M. Van Domselaar34, P. Ramírez-de la Piscina35, L. Ramos36, P. Almela37, M. Navarro-Llavat38, B. Botella39, J.P. Gisbert2, EVODIS

1Gastroenterology Unit, Hospital Universitario de La Princesa-IIS-IP and CIBEREHD, Madrid, Spain, 2Gastroenterology Unit, Hospital Universitario de La Princesa- IIS-IP and CIBEREHD, Madrid, Spain, 3Gastroenterology Unit, Complejo Hospitalario de Navarra- Instituto de Investigación Sanitaria de Navarra IdiSNA, Pamplona, Spain, 4Gastroenterlogy Unit, Hospital Universitario Reina Sofía- Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Córdoba, Spain, 5Gastroenterology Unit, Hospital Universitario de Valme and CIBEREHD, Sevilla, Spain, 6Gastroenterology Unit, Hospital Clínic i Provincial and CIBEREHD, Barcelona, Spain, 7Gastroenterology Unit, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, 8Gastroenterology Unit, Hospital Universitario Mutua Terrassa- and CIBEREHD, Terrassa, Spain, 9Gastroenterology Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain, 10Gastroenterology Unit, Hospital Clínico, Valencia, Spain, 11Gastroenterology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain, 12Gastroenterology Unit, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 13Gastroenterology Unit, Hospital Universitario Germans Trias i Pujol and CIBEREHD, Badalona, Spain, 14Gastroenterology Unit, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 15Gastroenterology Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain, 16Gastroenterology Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, 17Gastroenterology Unit, Hospital Universitario de Donostia- Instituto Biodonostia- Universidad del País Vasco UPV/EHU- and CIBEREHD, Donostia, Spain, 18Gastroenterology Unit, Hospital de Manises, Valencia, Spain, 19Gastroenterology Unit, Hospital Universitario Infanta Sofía, Madrid, Spain, 20Gastroenterology Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain, 21Gastroenterology Unit, Hospital Universitario Fundación de Alcorcón, Madrid, Spain, 22Gastroenterology Unit, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, 23Gastroenterology Unit, Hospital Universitario de Bellvitge, Barcelona, Spain, 24Gastroenterology Unit, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 25Gastroenterology Unit, Hospital Universitario de Fuenlabrada- Instituto de Investigación Sanitaria del Hospital La Paz IdiPAZ, Madrid, Spain, 26Gastroenterology Unit, Hospital Universitario Río Hortega, Valladolid, Spain, 27Gastroenterology Unit, Hospital Universitario La Fe- and CIBEREHD, Valencia, Spain, 28Gastroenterology Unit, Hospital Clínico Lozano Blesa- Instituto de Investigación Sanitaria Aragón IIS Aragón- and CIBEREHD, Zaragoza, Spain, 29Gastroenterology Unit, Hospital General de Ciudad Real, Ciudad Real, Spain, 30Gastroenterology Unit, Hospital General Universitario de Alicante- and CIBEREHD, Alicantesp, Spain, 31Gastroenterology Unit, Hospital General San Jorge, Huesca, Spain, 32Gastroenterology Unit, Hospital Universitario de Cáceres, Cáceres, Spain, 33Gastroenterology Unit, Hospital Universitario Infanta Leonor, Madrid, Spain, 34Gastroenterology Unit, Hospital de Torrejón de Ardoz, Madrid, Spain, 35Gastroenterology Unit, Hospital HUA Álava, Vitoria, Spain, 36Gastroenterology Unit, Hospital Universitario de Canarias, La Laguna, Spain, 37Gastroenterology Unit, Hospital General Universitario de Castellón, Castellón, Spain, 38Gastroenterology Unit, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain, 39Gastroenterology Unit, Hospital Universitario Infanta Cristina, Madrid, Spain

P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study

ECCO'20 Vienna

Year: 2020
Authors:

A. Yarur1, G.J. Mantzaris2, U. Kopylov3, M. Bassel4, N. Brett4, H. Kim5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, B. Bressler12

1Gastroenterology, Medical College of Wisconsin, Milwaukee, USA, 2Gastroenterology, Evangelismos Hospital, Athens, Greece, 3Sheba Medical Center, Gastroenterology, Tel Aviv, Israel, 4Evidera, Real-World Evidence, Montreal, Canada, 5Evidera, Data Analytics, Waltham, USA, 6Takeda Pharmaceuticals USA Inc., Medical Affairs, Deerfield, USA, 7Takeda Canada Inc., Medical Affairs, Oakville, Canada, 8Takeda Hellas S.A., Medical Affairs, Athens, Greece, 9Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 10Takeda Pharmaceuticals International, Evidence Generation and Publications, Singapore, Singapore, 11Takeda Pharmaceuticals International, Global Outcomes Research, Boston, USA, 12St. Paul’s Hospital, Gastroenterology, Vancouver, Canada

P388 Prediction model to safely CEASE anti-TNF therapy in Crohn’s disease: validation of a predictive diagnostic tool for the cessation of anti-TNF treatment in CD in a Dutch population

ECCO'20 Vienna

Year: 2020
Authors:

S. Ten Bokkel Huinink1, D. de Jong2, J. van der Woude1, D. Nieboer3, E. Steyerberg4, F. Wolfhagen5, B. van Tuyl6, R. West7, T. Romkens8, A. Tan9, F. Hoentjen10, W. Mares11, A. Bodelier12, G. Dijkstra13, R. Mallant14, N. de Boer15, J. Reinders16, P. van Boeckel17, G. Tack18, M. Duijvestein15, G. D’Haens2, A. de Vries1

1Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, 2Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands, 3Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands, 4Department of Clinical Biostatistics and Medical Decision Makin, Leiden University Medical Center, Leiden, The Netherlands, 5Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands, 6Diakonessenhuis, Gastroenterology and Hepatology, Utrecht, The Netherlands, 7Franciscus Gasthuis and Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 8Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, The Netherlands, 9Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands, 10Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, 11Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede-Wageningen, The Netherlands, 12Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands, 13Gastroenterology and Hepatology, University Medisch Centrum Groningen, Groningen, The Netherlands, 14Gastroenterology and Hepatology, Flevo Hospital, Almere, The Netherlands, 15Amsterdam University Medical Center, VU University Medical Center- AG&M Research Institute, Amsterdam, The Netherlands, 16Gastroenterology and Hepatology, Haga Hospital, Den Haag, The Netherlands, 17Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands, 18Gastroenterology and Hepatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands

P389 Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

K. van Hoeve1, E. Dreesen2, I. Hoffman1, M. Ferrante3, S. Vermeire3

1Department of Paediatric Gastroenterology and Hepatology and Nutrition, University Hospitals Leuven, Leuven, Belgium, 2Laboratory for Therapeutic and Diagnostic Antibodies- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 3Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

P390 New features of molecular diagnostics of the regulation of molecular apoptotic pathway in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A.A. Iakovlev, A. Volkov, I. Shcherbakova, G. Tarasova, S. Malakhanov, O. Bashtovaya

Department of Gastroenterology, Rostov State Medical University, Rostov-on-Don, Russian Federation

P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn’s ileitis: single-centre long-term outcome

ECCO'20 Vienna

Year: 2020
Authors:

G. Bislenghi1, M. Ferrante2, J.P.G. Sabino2, B. Verstockt2, B. Martin Perez1, A. Wolthuis1, S. Vermeire2, A. D’hoore1

1Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium, 2Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

P392 Initial experience with fibrin glue combined with infliximab treatment of postoperative anastomotic fistula in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

D. YAO

Department of General Surgery Shanghai Ninth People’s Hospital Shanghai Jiaotong University School of Medicine, No. 639 of Zhizaoju Road, General Surgery, Shanghai, China

P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy

ECCO'20 Vienna

Year: 2020
Authors:

A. Afzali1, A. Armuzzi2, Y. Bouhnik3, B. Bressler4, A. Hart5, D. Rubin6, M. Sans7, B. Siegmund8, D. Sninsky9

1*All authors are IBD Global Assessment of Patient Unmet Needs Survey (GAPPS) Steering Committee members (listed αbetically), 1The Ohio State University Wexner Medical Center, Inflammatory Bowel Disease, Columbus, USA, 2Fondazione Policlinico A. Gemelli IRCCS - Universita’ Cattolica, Gastroenterology, Rome, Italy, 3Inserm et Université Paris, Gastroenterology, Paris, France, 4Gastroenterology, Univeristy of British Columbia, Vancouver BC, Canada, 5Gastroenterology, St. Mark’s Hospital, London, UK, 6Gastroenterology- Hepatology and Nutrition, University of Chicago, Chicago, USA, 7Centro Médico Teknon, Gastroenterology, Barcelona, Spain, 8Gastroenterology- Infectiology and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 9Gastroenterology, Digestive Disease Associates, Gainesville, USA

P394 Preoperative factors associated with prolonged postoperative in-hospital length of stay in patients with Crohn’s disease undergoing intestinal resection or strictureplasty

ECCO'20 Vienna

Year: 2020
Authors:

T. Vinh Luong1, S. Dich Grandt2, I. Negoi3, S. Palubinskas2, A. El-Hussuna2

1Århus University Hospital, Nuclear Medicine and PET, Aalborg, Denmark, 2Aalborg University Hospital, Surgery, Skovlunde, Denmark, 3Carol Davila University of Medicine and Pharmacy Bucharest, Surgery, Bucharest, Romania

P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience

ECCO'20 Vienna

Year: 2020
Authors:

L. REZA1, E. Van Praag2, N. Iqbal1, C. Twum-Barima1, A. Hart3,4, S. Clark5,6, P. Tozer1,6

1St Mark’s Academic Institute, Fistula research Unit, London, UK, 2Academic Medical Centre, Colorectal surgery, Amsterdam, The Netherlands, 3St Mark’s Academic Institute, Inflammatory Bowel Disease Research Unit, London, UK, 4Imperial College, Faculty of Medicine, London, UK, 5St Mark’s Academic Institute, Colorectal Surgery, London, UK, 6Imperial College, Department of Surgery and Cancer, London, UK

P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects

ECCO'20 Vienna

Year: 2020
Authors:

C.A. Lee1, L. Acevedo1, D.A. Oh1, P. Baweja1, K. Gilder1, D. Han2, S. Jhee2, K. Komori1, S. Mullin1, T. Nguyen-Cleary1, K. Schmelzer2, Y. Tang1, J. Zhang1, J. Grundy1

1Arena Pharmaceuticals Inc., n/a, San Diego, USA, 2PAREXEL International, n/a, Waltham, USA

P397 Surveillance in ulcerative colitis: Can we predict the risk for intraepithelial neoplasia?

ECCO'20 Vienna

Year: 2020
Authors:

J. Estorninho1, P. Freire2, S. Lopes1, M. Ferreira1, M. Ferreira1, F. Portela1, P. Figueiredo1

1Centro Hospitalar e Universitário de Coimbra, Serviço de Gastrenterologia, Coimbra, Portugal, 2Faculdade de Medicina da Universidade de Coimbra, Gastrenterologia, Coimbra, Portugal

P398 The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD

ECCO'20 Vienna

Year: 2020
Authors:

X. Roblin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, S. nancey2, B. flourie2, S. paul3

1Department of Gastroenterology and Hepatology- Inserm- CIC1408, CHU Saint Etienne - Hospital Nord, Saint-Priest en Jarez, France, 2Department of Gastroenterology and Hepatology, CHU Lyon sud, Lyon, France, 3CHU Saint Etienne - Hospital Nord, Immunology, Saint-Priest en Jarez, France

P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort

ECCO'20 Vienna

Year: 2020
Authors:

B. Verstockt1, A. Outtier1, J. Lefrère1, J. Sabino1, S. Vermeire1, G. De Hertogh2, M. Ferrante2

1IBD Leuven, 1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2Laboratory of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium

P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy

ECCO'20 Vienna

Year: 2020
Authors:

C. Townsend, R. Khanna, A.S. Wilson

Gastroenterology, Western University, London, Canada

P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD

ECCO'20 Vienna

Year: 2020
Authors:

E. Shteyer1, R. Cytter-Kuint2, L. Winberg2

1Department of Pediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel, 2Departement of Radiology, Shaare Zedek Medical Center, Jerusalem, Israel